$100.00
Dual GIP/GLP-1 Metabolic Research
Tirzepatide is a synthetic peptide-based medication that activates both the GIP and GLP-1 receptors, creating a dual incretin mechanism.
This dual-pathway approach influences glucose-dependent insulin secretion, appetite regulation, and energy balance. Large clinical trials have demonstrated substantial effects on glycemic control and body weight.
Unlike many compounds in this collection, tirzepatide is an established prescription medication. In the United States, tirzepatide is approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management in eligible adults.
Research Focus: GIP signaling • GLP-1 signaling • Metabolic health • Body-weight regulation
Research Status: FDA-approved prescription medication for specific indications.
8 in stock
Dual GIP/GLP-1 Metabolic Research
Tirzepatide is a synthetic peptide-based medication that activates both the GIP and GLP-1 receptors, creating a dual incretin mechanism.
This dual-pathway approach influences glucose-dependent insulin secretion, appetite regulation, and energy balance. Large clinical trials have demonstrated substantial effects on glycemic control and body weight.
Unlike many compounds in this collection, tirzepatide is an established prescription medication. In the United States, tirzepatide is approved under the brand names Mounjaro for type 2 diabetes and Zepbound for chronic weight management in eligible adults.
Research Focus: GIP signaling • GLP-1 signaling • Metabolic health • Body-weight regulation
Research Status: FDA-approved prescription medication for specific indications.
